NEW YORK--(BUSINESS WIRE)-- Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results